Both share the GLP-1 class side-effect profile, led by gastrointestinal symptoms: nausea, vomiting, diarrhea, and constipation, worst during dose increases
They are now part of a broader medical discussion about obesity, insulin resistance, cardiovascular risk, fatty liver disease, inflammation, body composition, appetite signaling, and long-term metabolic health
Form into small meatballs, roughly one inch each
Furthermore, liraglutide, subcutaneous semaglutide, and tirzepatide are approved for chronic weight management regardless of diabetes status
Herein lies the importance of a balanced diet
doi:10.1016/j.metabol.2019.04.014 12